NCT05732428View on ClinicalTrials.gov

A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

March 29, 2024

Study Completion Date

November 1, 2024

Conditions
Breast Cancer
Interventions
DRUG

ARV-471

ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles

Trial Locations (3)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

130000

Jilin Province Tumor Hospital, Changchun

710061

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05732428 - A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China | Biotech Hunter | Biotech Hunter